Effect of 3-bromopyruvate and atovaquone on infection during in vitro interaction of Toxoplasma gondii and LLC-MK2 cells

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5239-5249

  De Lima, Loyze Paola O ^a,b   Seabra, Sergio H ^b   Carneiro, Henrique ^a   Barbosa, Helene S ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Centro Universitário Estadual da Zona Oeste UEZO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

3 BROMOPYRUVATE; AGGLUTININ; ANTIPROTOZOAL AGENT; ATOVAQUONE; LECTIN; PYRUVIC ACID DERIVATIVE; UNCLASSIFIED DRUG; BROMOPYRUVATE;

ANIMAL CELL; ARTICLE; BRADYZOITE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOLICHOS; DRUG EFFICACY; DRUG USE; HOST CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SCANNING ELECTRON MICROSCOPY; TACHYZOITE; TOXOPLASMA GONDII; TOXOPLASMOSIS; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; CELL LINE; DRUG EFFECTS; MOUSE; PATHOGENICITY; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL;

ANIMALS; ATOVAQUONE; CELL LINE; CELL PROLIFERATION; MACACA MULATTA; MICE; PYRUVATES; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL;

EID: 84940949875     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00337-15     Document Type: Article

References (43)

1. Tenter AM, Heckeroth AR, Weiss LM 2000. Toxoplasma gondii: from animals to human. Int J Parasitol 30:1217-1258. http://dx.doi.org/10.1016/S0020-7519(00)00124-7.
2. Black MW, Boothroyd JC 2000. Lytic cycle of Toxoplasma gondii. Microbiol Mol Biol Rev 64:607-623. http://dx.doi.org/10.1128/MMBR.64.3.607-623.2000.
3. Montoya JG, Liesenfeld O. 2004. Toxoplasmosis. Lancet 363:1965-1976. http://dx.doi.org/10.1016/S0140-6736(04)16412-X.
4. Diniz EMA, Vaz FAC. 2003. Qual é a recomendação atual para o tratamento da toxoplasmose congênita? Rev Assoc Med Bras 49:10. http://dx.doi.org/10.1590/S0104-42302003000100016.
5. Baggish AL, Hill DR 2002. Antiparasitic agent atovaquone. Antimicrob Agents Chemother 46:1163-1173. http://dx.doi.org/10.1128/AAC.46.5.1163-1173.2002.
6. Romand S, Della Bruna C, Farinotti R, Derouin F. 1996. In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii. Antimicrob Agents Chemother 40:2015-2020.
7. Meneceur P, Bouldouyre MA, Aubert D, Villena I., Menotti J, Sauvage V, Garin J.F., Derouin F. 2008. In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone. Antimicrob Agents Chemother 52:1269-1277. http://dx.doi.org/10.1128/AAC.01203-07.
8. Djurkovic-Djakovic O., Nikolic T, Robert-Gangneux F, Bobic B., Nikolic A. 1999. Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis. Antimicrob Agents Chemother 43:2240-2244.
9. Ko YH, Smith BL, Wang Y, Pomper M.G., Rini DA, Torbenson MS. 2004. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 324:269-275. http://dx.doi.org/10.1016/j.bbrc.2004.09.047.
10. Kim W, Yoon JH, Jeong J.M., Cheon GJ, Lee TS, Yang JI. 2007. Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. Mol Cancer Ther 6:2554-2562. http://dx.doi.org/10.1158/1535-7163.MCT-07-0115.
11. Cardaci S, Desideri E, Ciriolo MR 2012. Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug. J Bioenerg Biomembr 44:17-29. http://dx.doi.org/10.1007/s10863-012-9422-7.
12. Ko YH, Pedersen PL, Geschwind JF 2001. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173:83-91. http://dx.doi.org/10.1016/S0304-3835(01)00667-X.
13. Shoshan MC. 2012. 3-Bromopyruvate: targets and outcomes. J Bioenerg Biomembr 44:7-15. http://dx.doi.org/10.1007/s10863-012-9419-2.
14. El Sayed S.M., Mohamed WG, Seddik M.A., Ahmed AS, Mahmoud AG, Amer WH, Helmy Nabo MM, Hamed AR, Ahmed NS, Abd-Allah AA. 2014. Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study. Chin J Cancer 33:356-364.
15. Pereira da Silva AP, El-Bacha T, Kyaw N., dos Santos RS, da-Silva WS, Almeida FC, Da Poian AT, Galina A. 2009. Inhibition of energyproducing pathways of HepG2 cells by 3-bromopyruvate. Biochem J 417: 717-726. http://dx.doi.org/10.1042/BJ20080805.
16. Ganapathy-Kanniappan S., Geschwind JF, Kunjithapatham R, Buijs M., Vossen JA, Tchernyshyov I, Cole RN, Syed L.H., Rao PP, Ota S, Vali M. 2009. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. Anticancer Res 29:4909-4918.
17. Lis P, Zarzycki M, Ko Y.K., Casal M., Pedersen PL, Goffeau A, Ułaszewski S. 2012. Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae. J Bioenerg Biomembr 44:155-161. http://dx.doi.org/10.1007/s10863-012-9421-8.
18. Dylag M, Lis P, Niedzwiecka K., Ko YH, Pedersen PL, Goffeau A, Ułaszewski S. 2013. 3-Bromopyruvate: a novel antifungal agent against the human pathogen Cryptococcus neoformans. Biochem Biophys Res Commun 434:322-327. http://dx.doi.org/10.1016/j.bbrc.2013.02.125.
19. Barnard JP, Reynafarje B, Pedersen PL 1993. Glucose catabolism in African trypanosomes: evidence that the terminal step is catalyzed by a pyruvate transporter capable of facilitating uptake of toxic analogs. J Biol Chem 268:3654-3661.
20. Vanderheyden N, Wong J, Docampo R. 2000. A pyruvate-proton symport and an H+-ATPase regulate the intracellular pH of Trypanosoma brucei at different stages of its life cycle. Biochem J 346:53-62. http://dx.doi.org/10.1042/0264-6021:3460053.
21. Zhang YW, Halonen SK, Ma Y.F., Wittner M., Weiss LM. 2001. Initial characterization of CST1, a Toxoplasma gondii cyst wall glycoprotein. Infect Immun 69:501-507.
22. Flood PP. 1975. Scanning electron microscope observations on the muscle innervation of Oikopleura dioica Fol (Appendicularia, Tunicata) with notes on the arrangement of connective tissue fibres. Cell Tissue Res 164: 357-369.
23. De Souza W., Campanati L, Attias M. 2008. Strategies and results of field emission scanning electron microscopy (FE-SEM) in the study of parasitic protozoa. Micron 39:77-87. http://dx.doi.org/10.1016/j.micron.2006.11.003.
24. Pedersen PL. 2012. 3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective "small molecule" anti-cancer agent taken from labside to bedside: introduction to a special issue. J Bioenerg Biomembr 44:1-6. http://dx.doi.org/10.1007/s10863-012-9425-4.
25. Dubey JP, Lindsay DS, Speer CA 1998. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev 11:267-299.
26. Fleige T, Fischer K, Ferguson D.J., Gross U., Bohne W. 2007. Carbohydrate metabolism in the Toxoplasma gondii apicoplast: localization of three glycolytic isoenzymes, the single pyruvate dehydrogenase complex, and a plastid phosphate translocator. Eukaryot Cell 6:984-996. http://dx.doi.org/10.1128/EC.00061-07.
27. Denton H, Roberts CW, Alexander J, Thong K.W., Coombs GH. 1996. Enzymes of energy metabolism in the bradyzoites and tachyzoites of Toxoplasma gondii. FEMS Microbiol Lett 137:103-108. http://dx.doi.org/10.1111/j.1574-6968.1996.tb08090.x.
28. Vercesi A, Rodrigues CO, Uyemura A.S., Zhong L., Moreno SNJ. 1998. Respiration and oxidative phosphorylation in the Apicomplexan parasite Toxoplasma gondii. J Biol Chem 273:31040-31047. http://dx.doi.org/10.1074/jbc.273.47.31040.
29. Nelson K. 2002. 3-Bromopyruvate kills cancer cells in animals. Lancet Oncol 3:524. http://dx.doi.org/10.1016/S1470-2045(02)00867-7.
30. Geschwind JF, Ko YH, Torbenson M.S., Magee C., Pedersen PL. 2002. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 62:3909-3913.
31. Pedersen PL. 2007. Warburg, me and hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg effect," i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39:211-222. http://dx.doi.org/10.1007/s10863-007-9094-x.
32. Vellieux FM, Hajdu J, Verlinde C.L., Groendijk H., Read RJ, Greenhough TJ, Campbell JW, Kalk K.H., Littlechild JA, Watson HC. 1993. Structure of glycosomal glyceraldehyde-3-phosphate dehydrogenase from Trypanosoma brucei determined from Laue data. Proc Natl Acad Sci U S A 90: 2355-2359. http://dx.doi.org/10.1073/pnas.90.6.2355.
33. Satchell JF, Malby RL, Luo C.S., Adisa A., Alpyurek AE, Klonis N, Smith BJ, Tilley L, Colman PM 2005. Structure of glyceraldehyde-3-phosphate dehy-drogenase from Plasmodium falciparum. Acta Crystallogr D-Biol Crystallogr 61:1213-1221. http://dx.doi.org/10.1107/S0907444905018317.
34. Liu XH, Zheng XF, Wang YL 2009. Inhibitive effect of 3-bromopyruvic acid on human breast cancer MCF-7 cells involves cell cycle arrest and apoptotic induction. Chin Med J (Engl) 122:1681-1685.
35. Martins-Duarte E.S., de Souza W, Vommaro RC. 2008. Itraconazole affects Toxoplasma gondii endodyogeny. FEMS Microbiol Lett 282:290-298. http://dx.doi.org/10.1111/j.1574-6968.2008.01130.x.
36. Egger L, Schneider J, Rheme C., Tapernoux M, Hacki J, Borner C. 2003. Serine proteases mediate apoptosis-like cell death and phagocytosis under caspase-inhibiting conditions. Cell Death Differ 10:1188-1203. http://dx.doi.org/10.1038/sj.cdd.4401288.
37. Xu C, Bailly-Maitre B, Reed JC. 2005. Endoplasmic reticulum stress: cell life and death decisions. JClin Invest 115:2656-2664. http://dx.doi.org/10.1172/JCI26373.
38. Ganapathy-Kanniappan S., Geschwind JF, Kunjithapatham R, Buijs M., Syed LH, Rao PP, Ota S, Kwak B.K., Loffroy R., Vali M. 2010. 3-Bromopyruvate induces endoplasmic reticulum stress, overcomes autophagy and causes apoptosis in human HCC cell lines. Anticancer Res 30:923-935.
39. Paredes-Santos T.C., Martins-Duarte ES, Vitor R.W., de Souza W, Attias M, Vommaro RC 2013. Spontaneous cystogenesis in vitro of a Brazilian strain of Toxoplasma gondii. Parasitol Int 62:181-188. http://dx.doi.org/10.1016/j.parint.2012.12.003.
40. Ferreira-da-Silva MF, Rodrigues RM, Andrade EF, Carvalho L, Gross U, Lüder CGK, Barbosa HS. 2009. Spontaneous stage differentiation of mouse-virulentToxoplasma gondii RH parasitesinskeletal muscle cells: an ultrastructural evaluation. Mem Inst Oswaldo Cruz 104:196-200. http://dx.doi.org/10.1590/S0074-02762009000200012.
41. Kohler S, Delwiche CF, Denny P.W., Tilney LG, Webster P, Wilson RJ, Roos DS 1997. A plastid of probable green algal origin in Apicomplexan parasites. Science 275:1485-1489. http://dx.doi.org/10.1126/science.275.5305.1485.
42. Gleeson MT. 2000. The plastid in Apicomplexa: what use is it? Int J Parasitol 30:1053-1070. http://dx.doi.org/10.1016/S0020-7519(00)00100-4.
43. Mazumdar J, Wilson EH, Masek K, Hunter C.A., Striepen B. 2006. Apicoplast fatty acid synthesis is essential for organelle biogenesis and parasite survival in Toxoplasma gondii. Proc Natl Acad Sci U S A 103: 13192-12197. http://dx.doi.org/10.1073/pnas.0603391103.